Navigation Links
Cancer researchers receive NIH grant to advance brain tumor therapies from lab to clinical trials
Date:4/24/2008

Cancer researchers at Childrens Hospital of Pittsburgh of UPMC and the University of Pittsburgh Cancer Institute (UPCI) will further develop novel treatments for brain tumors through a new, five-year, $6.24 million grant to the University of Pittsburgh School of Medicine.

The grant from the National Institute of Neurological Disorders and Stroke (NINDS) will fund three projects aimed at developing cutting-edge treatment strategies for a type of brain tumor known as gliomas. The projects are led by principal investigator Ian Pollack, MD, chief of the Division of Pediatric Neurosurgery at Childrens Hospital and director of the UPCI Brain Tumor Program. This is the second five-year grant the Brain Tumor Program project has received from the NINDS.

In the laboratory over the last five years, our researchers have developed three unique and promising approaches to treating gliomas, which are the most common form of brain tumors, Dr. Pollack said. Over the next five years, our goal is to take these approaches from the laboratory to clinical trial and begin to have a direct impact on patients diagnosed with brain tumors.

The three projects and their respective investigators are:

  • Molecularly targeted therapies that interrupt the signaling pathways in the brain that drive tumor growth Dr. Pollack, also the Walter Dandy Professor of Neurosurgery at the University of Pittsburgh School of Medicine

  • Immunotherapy using segments of proteins that are overexpressed by brain tumors to vaccinate patients against tumor growth Hideho Okada, MD, PhD, associate professor in the departments of Neurological Surgery and Surgery at the University of Pittsburgh School of Medicine

  • Viral vectors (a modified herpes virus) to kill tumor cells while leaving other cells intact Joseph C. Glorioso III, PhD, chair of the Department of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine; and Paola Grandi, PhD, an assistant professor in the departments of Neurological Surgery and Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine

Every year about 19,000 children and adults are diagnosed with primary brain tumors, according to the National Cancer Institute. Malignant gliomas are the most common, accounting for more than half and including astrocytomas, oligodendrogliomas and glioblastoma multiforme.

Current conventional therapies for malignant brain tumors, including surgery, radiation and chemotherapy, are often unsatisfactory for controlling these tumors, and the vast majority recur, Dr. Pollack said. We believe the projects here in Pittsburgh hold promise in improving the treatment of these challenging tumors.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... VA (PRWEB) , ... June 23, 2017 , ... ... of what is needed and will ultimately do significant harm to people with ... to everyone. , "While it leaves in place the Affordable Care Act ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
(Date:6/23/2017)... ... 2017 , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique ... a proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does ... patients can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia ... 21 leaders from government, business and civil society in 11 countries across the Middle ... fall, engaging in a transformative exchange of knowledge and ideas with the leading minds ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: